The RANKL/OPG System is Activated in Inflammatory Bowel Disease and Relates to the State of Bone Loss

Overview

Journal Gut

Specialty Gastroenterology

Date 2005 Mar 9

PMID 15753532

Citations 82

Authors

A R Moschen

A Kaser

B Enrich

O Ludwiczek

M Gabriel

P Obrist

A M WOLF

H Tilg

Affiliations

Soon will be listed here.

Abstract

Background And Aims: A substantial proportion of patients with inflammatory bowel disease (IBD) develops osteopenia and osteoporosis in the course of disease. Recent data from a mouse model of colitis suggest that the receptor activator of nuclear factor kappa B (RANKL)/osteoprotegerin (OPG) system may be responsible for bone loss.

Methods: We investigated the activation state of the RANKL/OPG system and its association with bone loss in human IBD. Plasma levels of OPG and RANKL were correlated with bone mineral density and current IBD therapy. Colonic secretion of OPG and RANKL and cell types responsible for such secretion were determined.

Results: OPG plasma levels were elevated 2.4-fold in Crohn's disease (CD) and 1.9-fold in ulcerative colitis (UC) whereas soluble RANKL (sRANKL) levels were not significantly different in IBD patients compared with healthy controls. High levels of OPG were released from colonic explant cultures (CEC) derived from inflamed IBD specimens, and colonic macrophages and dendritic cells costained for OPG. sRANKL levels from CEC were low both in IBD patients and healthy controls. Interestingly, increased expression of RANKL was mainly confined to cells in the lamina muscularis. A significant negative correlation was found between OPG plasma levels and femoral neck/lumbar spine bone mineral density.

Conclusions: We have demonstrated that IBD is associated with alterations in the RANKL/OPG system. Applying results from a murine model of colitis associated bone loss, the constellation of OPG and sRANKL regulation observed in our study raises the possibility that RANKL/OPG may contribute to the development of bone loss in IBD.

Citing Articles

The effect of hypersensitive C-reactive protein to albumin ratio on the risk of fragility fracture in the Chinese male population.

Guo L, Zhang N, Fan X, Hou X, Li M, Xu W Osteoporos Int. 2025; .

PMID: 39982456 DOI: 10.1007/s00198-025-07428-x.

Is There Any Association Between Fat Body Mass and Bone Mineral Density in Patients with Crohn's Disease and Ulcerative Colitis?.

Ratajczak-Pawlowska A, Michalak M, Szymczak-Tomczak A, Rychter A, Zawada A, Skoracka K Nutrients. 2025; 17(3).

PMID: 39940324 PMC: 11820439. DOI: 10.3390/nu17030466.

14-3-3ζ suppresses RANKL signaling by destabilizing TRAF6.

Ayyasamy R, Fan S, Czernik P, Lecka-Czernik B, Chattopadhyay S, Chakravarti R J Biol Chem. 2024; 300(7):107487.

PMID: 38908751 PMC: 11331427. DOI: 10.1016/j.jbc.2024.107487.

Advances in the pharmacological effects and molecular mechanisms of emodin in the treatment of metabolic diseases.

Yu L, Zhao Y, Zhao Y Front Pharmacol. 2023; 14:1240820.

PMID: 38027005 PMC: 10644045. DOI: 10.3389/fphar.2023.1240820.

Effects of distinct Polycystic Ovary Syndrome phenotypes on bone health.

Mills E, Abbara A, Dhillo W, Comninos A Front Endocrinol (Lausanne). 2023; 14:1163771.

PMID: 37251667 PMC: 10213631. DOI: 10.3389/fendo.2023.1163771.

References

Silvennoinen J, Karttunen T, Niemela S, Manelius J, Lehtola J . A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut. 1995; 37(1):71-6. PMC: 1382771. DOI: 10.1136/gut.37.1.71. View

Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M . Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology. 1995; 108(2):417-22. DOI: 10.1016/0016-5085(95)90068-3. View

Bernstein C, Leslie W . The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol. 2003; 15(8):857-64. DOI: 10.1097/00042737-200308000-00004. View

Szalay F, Hegedus D, Lakatos P, Tornai I, Bajnok E, Dunkel K . High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol. 2003; 38(4):395-400. DOI: 10.1016/s0168-8278(02)00435-x. View

Lacey D, Timms E, Tan H, Kelley M, Dunstan C, Burgess T . Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93(2):165-76. DOI: 10.1016/s0092-8674(00)81569-x. View

Kong Y, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S . Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999; 402(6759):304-9. DOI: 10.1038/46303. View

Kirchgatterer A, Wenzl H, Aschl G, Hinterreiter M, Stadler B, Hinterleitner T . Examination, prevention and treatment of osteoporosis in patients with inflammatory bowel disease: recommendations and reality. Acta Med Austriaca. 2002; 29(4):120-3. DOI: 10.1046/j.1563-2571.2002.02018.x. View

Romas E, Gillespie M, Martin T . Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone. 2002; 30(2):340-6. DOI: 10.1016/s8756-3282(01)00682-2. View

Ashcroft A, Cruickshank S, Croucher P, Perry M, Rollinson S, Lippitt J . Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity. 2003; 19(6):849-61. DOI: 10.1016/s1074-7613(03)00326-1. View

10.

de Jong D, Corstens F, Mannaerts L, van Rossum L, Naber A . Corticosteroid-induced osteoporosis: does it occur in patients with Crohn's disease?. Am J Gastroenterol. 2002; 97(8):2011-5. DOI: 10.1111/j.1572-0241.2002.05916.x. View

11.

. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

12.

Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. DOI: 10.1016/s0092-8674(00)80209-3. View

13.

. American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003; 124(3):791-4. DOI: 10.1053/gast.2003.50107. View

14.

Best W, Becktel J, SINGLETON J, KERN Jr F . Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70(3):439-44. View

15.

Hofbauer L, Lacey D, Dunstan C, Spelsberg T, Riggs B, Khosla S . Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone. 1999; 25(3):255-9. DOI: 10.1016/s8756-3282(99)00162-3. View

16.

Lamb E, Wong T, Smith D, Simpson D, Coakley A, Moniz C . Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2002; 16(11):1895-902. DOI: 10.1046/j.1365-2036.2002.01363.x. View

17.

Theill L, Boyle W, Penninger J . RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol. 2002; 20:795-823. DOI: 10.1146/annurev.immunol.20.100301.064753. View

18.

Bernstein C, Leslie W, LeBoff M . AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003; 124(3):795-841. DOI: 10.1053/gast.2003.50106. View

19.

Strober W, Fuss I, Blumberg R . The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002; 20:495-549. DOI: 10.1146/annurev.immunol.20.100301.064816. View

20.

Robinson R, Al-Azzawi F, Iqbal S, Kryswcki T, Almond L, Abrams K . Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci. 1998; 43(11):2500-6. DOI: 10.1023/a:1026650719552. View